Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Single, Ascending Dose Evaluation of the Safety, Pharmacokinetics of Methylone in Healthy Subjects
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Transcend Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT06303648
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Transcend Therapeutics
- Target Recruit Count
- 150
- Registration Number
- NCT06237426
- Locations
- 🇺🇸
Mountain View Clinical Research, Denver, Colorado, United States
🇺🇸Sunstone Medical, Rockville, Maryland, United States
🇺🇸Cedar Clinical Research, Inc, Draper, Utah, United States
An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Transcend Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT06215261
- Locations
- 🇺🇸
Segal Trials, Lauderhill, Florida, United States
🇺🇸Accel Research, Maitland, Florida, United States
🇺🇸CNS Healthcare, Orlando, Florida, United States
A Study to Assess the Use of Methylone in the Treatment of PTSD
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Transcend Therapeutics
- Target Recruit Count
- 79
- Registration Number
- NCT05741710
- Locations
- 🇺🇸
Mountain View Clinical Research, Denver, Colorado, United States
🇺🇸Clinical Neuroscience Solutions - Jacksonville, Jacksonville, Florida, United States
🇺🇸Accel Research Sites, Maitland, Florida, United States
News
FDA Grants Breakthrough Therapy Designation to TSND-201 for PTSD Treatment
The FDA has granted Breakthrough Therapy designation to TSND-201 (methylone) for PTSD treatment, potentially expediting its development and review process.